Feature Channels

Pharmaceuticals

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Velocity Pharmaceutical Development, Llc and Tigercat Pharma, Inc. Announce Phase 2 Results for Vpd-737 in Patients with Chronic Pruritus

/PRNewswire/ -- Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the current standard of care, including topical steroids and antihistamines.

View | Comment

Science

Channels:

Keywords:

'Darwinian' Test Uncovers an Antidepressant's Hidden Toxicity

D49B0739.jpg

The organismal performance assay detects subtle toxic effects by subjecting mice to a relentless, Darwinian competition for food, shelter and mates. If there is a defect in any physiological system, it is more likely to stand out if test animals have to compete for resources.

View

Medicine

Channels:

Keywords:

Mayo Clinic: Genotyping Errors Plague CYP2D6 Testing for Tamoxifen Therapy

Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of a Mayo Clinic study published in the Journal of the National Cancer Institute.

View | Comment

Medicine

Channels:

Keywords:

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload Immunotherapy

DraganPhoto.JPG

If approved, Iomab-B should increase the number of patients eligible for curative bone marrow transplant (BMT, also known as HSCT) and improve clinical outcomes.

View | Comment

Medicine

Channels:

New Development in Cell Therapy: Veto Cell Technology

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation. Scientists are investigating whether Veto Cell technology, which selectively tunes immune response, can change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated. Itamar Shimat, Cell Source’s CEO is available to talk about his company’s recent breakthroughs with Veto Cell technology.

View | Comment

Life

Law and Public Policy

Channels:

Pharmacy Law Expert

millardw.jpg

Assistant Dean Mike Millard, a member of the Oregon Governor's Task Force on Prescription Drug Abuse, can speak about current law and policy.

View | Comment

Medicine

Channels:

Keywords:

HIV Drug Blocks Bone Metastases in Prostate Cancer

The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread

View | Comment

Medicine

Channels:

Keywords:

“Dramatic” Early Phase 1 Results for AG-120 in IDH1 Mutated AML

University of Colorado Cancer Center study shows "extremely promising” early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH.

View | Comment

Medicine

Channels:

Keywords:

Life's Extremists May Be an Untapped Source of Antibacterial Drugs

Vent_PillBottlesV2.jpg.jpeg

Life's extremists, a family of microbes called Archaea, may be an untapped source of new antibacterial drugs. That conclusion arises from the discovery of the first antibacterial gene in this ancient lineage.

View | Comment

Medicine

Channels:

Keywords:

First-In-Class Nasal Spray Demonstrates Promise for Migraine Pain Relief

Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines.

View | Comment